Scarica l'app Stockscreener
4.53
5.89%
0.252
Pre-mercato:
4.49
-0.04
-0.88%
Precedente Chiudi:
$4.278
Aprire:
$4.54
Volume 24 ore:
5,086
Relative Volume:
0.39
Capitalizzazione di mercato:
$183.13M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-6.1708
EPS:
-0.7341
Flusso di cassa netto:
-
1 W Prestazione:
+23.45%
1M Prestazione:
+34.67%
6M Prestazione:
-21.76%
1 anno Prestazione:
+23.77%
Intervallo 1D:
$4.53
$4.73
Intervallo di 1 settimana:
$3.90
$4.73
Portata 52W:
$2.55
$6.4229
Genfit Adr Stock (GNFT) Company Profile
Confronta GNFT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GNFT
Genfit Adr
|
4.53 | 183.13M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
Genfit Adr Stock (GNFT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-12-20 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2020-07-23 | Aggiornamento | Stifel | Hold → Buy |
| 2020-06-25 | Iniziato | BofA/Merrill | Underperform |
| 2020-05-13 | Downgrade | Kepler | Buy → Reduce |
| 2020-05-12 | Downgrade | Barclays | Overweight → Equal Weight |
| 2020-05-12 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2019-10-29 | Reiterato | B. Riley FBR | Buy |
| 2019-06-25 | Iniziato | Stifel | Hold |
| 2019-04-24 | Iniziato | SVB Leerink | Outperform |
| 2019-04-22 | Iniziato | Barclays | Overweight |
Mostra tutto
Genfit Adr Borsa (GNFT) Ultime notizie
European ADRs Show Strength With Genfit And Novo Nordisk Leading Gains - Finimize
European Equities Traded in the US as American Depositary Receipts Higher in Friday Trading - TradingView
European ADRs Climb As Biopharmaceuticals Lead The Charge - Finimize
European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Fall in Thursday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Tread Water in Tuesday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Edge Higher in Thursday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Decline in Wednesday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Higher in Monday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Edge Lower in Tuesday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Down for Week - TradingView
European Equities Traded in the US as American Depositary Receipts Track Lower in Thursday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Climb Higher in Wednesday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Surge Higher in Monday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Remain Flat for Week - TradingView
GENFIT annonce les résultats préliminaires de l’Offre de Rachat proposée aux porteurs d’OCEANEs 2025 et la Convocation de l’assemblée générale des porteurs d’OCEANEs 2025 - GlobeNewswire Inc.
European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading, Up 1% for Week - TradingView
European Equities Traded in the US as American Depositary Receipts Rise Sharply in Wednesday Trading - TradingView
GENFIT: Historic Milestone Achieved with U.S. FDA - GlobeNewswire
Ipsen and GENFIT Announce Positive Results from Phase III ELATIVE trial of elafibranor in patients with primary biliary cholangitis, a rare cholestatic liver disease - Ipsen
Ipsen und GENFIT schließen im Rahmen einer langfristigen globalen Partnerschaft eine exklusive Lizenzvereinbarung für Elafibranor ab, ein Phase-III-Asset, das für die Behandlung von primärer biliärer Cholangitis geprüft wird - Business Wire
Ipsen and GENFIT Enter Into Exclusive Licensing Agreement for Elafibranor, a Phase III Asset Evaluated in Primary Biliary Cholangitis, as Part of a Long-Term Global Partnership - Business Wire
Genfit Adr Azioni (GNFT) Dati Finanziari
Non sono disponibili dati finanziari per Genfit Adr (GNFT). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
0.39%
3.66%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):